Avedro Broadens Cross-Link Product Line

Avedro Broadens Cross-Link Product Line
Corneal collagen cross-linking has been a vexing specialty for US-based companies trying to guide a product through a cautious FDA. But Massachusetts-based Avedro Inc., continues to establish a meaningful portfolio in the space through deals like the acquisition of Switzerland-based IROC Innocross AG.

Avedro acquired the assets of IROC Innocross, which was the first company to commercialize a cross-linking device for the treatment of keratoconus and other corneal pathologies, according to a release announcing the deal.

Avedro CEO David Muller says the deal makes Avedro

the only cross-linking company to address the entire market for corneal cross-linking procedures across all price points, allowing our seasoned distribution network to aggressively compete for and win the business of any ophthalmologist in the cross-linking space.”

First developed in Germany in the late 1990s, corneal cross-linking combines ultra-violet light and riboflavin eye drops to stabilize the cornea, according to the company. This limits the progression of keratoconus, a non-inflammatory eye condition that weakens the cornea.

At the April OIS@ASCRS, Muller participated in a short debate about whether cross-linking should be performed with a portion of the corneal epithelial off or on. Watch that exchange, as well as a panel discussion featuring venture capitalists, physicians and entrepreneurs as they review this opportunity in cross-linking, here.

Additionally, check back for an OIS Podcast featuring Muller coming soon.



Pod 312 - Brian Strem - NL

Passionate Pursuits With Kiora Pharmaceuticals Brian Strem

Pod 311 - Lori-Ann Christie - Thumbnail

Lori-Ann Christie’s Detour to Venture Capital With Visionary Ventures

Diana Driscoll - OIS Podcast 309 - Thumbnail

Calculating Both Sides of the Doctor-Patient Equation, with Diana Driscoll, OD

MicrosoftTeams-image (62)

Oyster Point Ramps Up for Tyrvaya, First Dry Eye Nasal Spray

Pod 306 Bill McPhee - Thumb

Faster, Better, Smarter, Cheaper With MacuLogix’s Bill McPhee

the oral retina drugs are coming

Six Oral Retina Drug Development Programs to Watch

About The Author

Tom Salemi

Tom serves as Content Director for Healthegy, joining the company in 2014, to create and manage a new line of podcasts, publications and other editorial products. At Healthegy, Tom hosts the OIS Podcast and MedtechTalk, contributes to the Engage and Eye on Innovation newsletters and assists in the agenda development of new and existing conferences.


Get The Latest News In Opthalmologic Innovation To Your Inbox.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.


Get our monthly newsletter about the latest in opthalmologic innovation.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.